全文获取类型
收费全文 | 385119篇 |
免费 | 25490篇 |
国内免费 | 3263篇 |
专业分类
耳鼻咽喉 | 5226篇 |
儿科学 | 8301篇 |
妇产科学 | 10191篇 |
基础医学 | 53880篇 |
口腔科学 | 11879篇 |
临床医学 | 30955篇 |
内科学 | 79261篇 |
皮肤病学 | 8581篇 |
神经病学 | 27536篇 |
特种医学 | 14340篇 |
外国民族医学 | 86篇 |
外科学 | 61219篇 |
综合类 | 11143篇 |
现状与发展 | 5篇 |
一般理论 | 67篇 |
预防医学 | 17953篇 |
眼科学 | 9590篇 |
药学 | 31617篇 |
12篇 | |
中国医学 | 2588篇 |
肿瘤学 | 29442篇 |
出版年
2021年 | 2964篇 |
2019年 | 2933篇 |
2018年 | 4717篇 |
2017年 | 3615篇 |
2016年 | 3726篇 |
2015年 | 4324篇 |
2014年 | 6064篇 |
2013年 | 7667篇 |
2012年 | 10484篇 |
2011年 | 10745篇 |
2010年 | 6541篇 |
2009年 | 6107篇 |
2008年 | 9771篇 |
2007年 | 10606篇 |
2006年 | 10540篇 |
2005年 | 9643篇 |
2004年 | 9049篇 |
2003年 | 8757篇 |
2002年 | 8434篇 |
2001年 | 28454篇 |
2000年 | 28974篇 |
1999年 | 23823篇 |
1998年 | 5269篇 |
1997年 | 4368篇 |
1996年 | 3929篇 |
1995年 | 3553篇 |
1994年 | 3181篇 |
1993年 | 2888篇 |
1992年 | 16092篇 |
1991年 | 14847篇 |
1990年 | 14185篇 |
1989年 | 13979篇 |
1988年 | 12596篇 |
1987年 | 12072篇 |
1986年 | 11118篇 |
1985年 | 10327篇 |
1984年 | 6916篇 |
1983年 | 5607篇 |
1982年 | 2719篇 |
1979年 | 5482篇 |
1978年 | 3347篇 |
1977年 | 2971篇 |
1975年 | 2641篇 |
1974年 | 3064篇 |
1973年 | 2865篇 |
1972年 | 2828篇 |
1971年 | 2773篇 |
1970年 | 2510篇 |
1969年 | 2543篇 |
1968年 | 2250篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
26.
27.
miR-30c has been acknowledged as a tumor suppressor in various human cancers, such as ovarian cancer, gastric cancer, and prostate cancer. However, the role of miR-30c in glioblastoma (GBM) needs to be investigated.
In our study, we found that the expression of miR-30c was significantly downregulated in GBM tissues and
cell lines. We found that overexpression of miR-30c inhibited cellular proliferation of GBM cells in vitro and
in vivo. More GBM cells were arrested in the G0 phase after miR-30c overexpression. Moreover, we showed
that miR-30c overexpression suppressed the migration and invasion of GBM cells. Mechanistically, we found
that SOX9 was a direct target of miR-30c in GBM cells. Overexpression of miR-30c inhibited the mRNA
and protein levels of SOX9 in GBM cells. Moreover, there was a negative correlation between the expression
of miR-30c and SOX9 in GBM tissues. Finally, we showed that restoration of SOX9 in GBM cells reversed
the proliferation, migration, and invasion of GBM cells transfected with miR-30c mimic. Collectively, our
results demonstrated that miR-30c suppressed the proliferation, migration, and invasion of GBM cells via
targeting SOX9. 相似文献
28.
舌癌患者手术及放化疗后会出现构音障碍、吞咽困难、口腔黏膜炎、口干、营养不良等并发症,使患者生存质量下降,甚至导致肿瘤的复发转移,影响生存期,单一方法往往顾此失彼。依托于中国中医科学院西苑医院肿瘤康复基地,杨宇飞教授在国内外调研考察基础上,结合中国国情,构建了一种“门诊多学科肿瘤康复模式”,在舌癌康复方面,以患者为中心,以中医肿瘤内科为主导,多学科共同参与,结合康复科、口腔科、营养科、药剂科等各科优势,形成全程个体化规范序贯康复方案,对患者及早进行康复,在放疗前进行预防性干预尤其重要,使患者能够快速缓解手术和放疗的不良反应,患者获益明显。现取两个典型案例总结其舌癌多学科康复的经验,以期为舌癌的康复提供借鉴。 相似文献
29.
30.
Mariano E. Menendez Suleiman Y. Sudah Patrick J. Denard 《Seminars in Arthroplasty》2022,32(3):644-649
BackgroundThe growing enthusiasm for the use of reverse shoulder arthroplasty (RSA) in the treatment of primary glenohumeral osteoarthritis (GHOA) with an intact rotator cuff is based on data derived from single-center studies with limited generalizability and follow-up. This study compared patient-reported outcomes (PROs) between RSA and total shoulder arthroplasty (TSA) for the treatment of primary GHOA with up to 5-year follow-up and examined temporal trends in the treatment of GHOA between 2012 and 2021.MethodsA retrospective review was performed on patients with primary GHOA undergoing primary arthroplasty surgery from the Surgical Outcomes System global registry between 2012 and 2021. PROs including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, and visual analog scale (VAS) for pain were compared between RSA and TSA at 1, 2, and 5 years postoperatively.ResultsA total of 4451 patients were included, with 2693 (60.5%) undergoing TSA and 1758 (39.5%) undergoing RSA. Both RSA and TSA provided clinically excellent outcomes at 1 year postoperatively (ASES: 80.8 ± 17.9 vs. 85.9 ± 15.2, respectively; SANE: 74.8 ± 24.7 vs. 79.5 ± 22.9; VAS pain: 1.3 ± 2.0 vs. 1.1 ± 1.7; all P < .05) that were maintained at 2 years (ASES: 81.3 ± 19.3 vs. 87.3 ± 14.9; SANE: 74.8 ± 26.2 vs. 79.7 ± 24.7; VAS pain: 1.3 ± 2.1 vs. 1.0 ± 1.6; all P < .05) and 5 years (ASES: 81.7 ± 16.5 vs. 86.9 ± 15.3; SANE: 71.6 ± 28.5 vs. 78.2 ± 25.9; VAS pain: 1.0 ± 1.7 vs. 1.0 ± 1.7; all P < .05), with statistical significance favoring TSA. After controlling for age and sex, there was an adjusted difference of 4.5 units in the ASES score favoring TSA (P = .005) at 5 years postoperatively but no differences in adjusted SANE (P = .745) and VAS pain (P = .332) scores. The use of RSA for GHOA grew considerably over time, from representing only 17% of all replacements performed for GHOA in 2012 to nearly half (47%) in 2021 (P < .001).ConclusionRSA as a treatment for GHOA with an intact rotator cuff seems to yield PROs that are largely clinically equivalent to TSA extending to 5 years postoperatively. The observed statistical significance favoring TSA appears to be of marginal clinical benefit based on established minimal clinically important differences and may be a result of the large sample size. Further research using more granular clinical data and examining differences in range of motion and complications is warranted as it may change the value analysis. 相似文献